ArticleiGIE : innovation, investigation and insights2023
Utilization of methylene blue-based submucosal injection to identify residual neuroendocrine tumor in the colon after endoscopic biopsy sampling.
Article in iGIE : innovation, investigation and insights, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.ACS omega · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A woman underwent colonoscopy with biopsy sampling that revealed a tiny neuroendocrine tumor (NET) about 5 cm from the anus. After several months, the biopsy sampling site healed completely, making the identification of the residual NET difficult. The specific location of the lesion could not be confirmed even under magnifying endoscopy and EUS. When a higher concentration of methylene blue was injected into the submucosa, the residual lesion was exposed. The endoscopist then inferred the likely location of the lesion on magnifying endoscopy on the basis of the marker and the location of the lesion after injection of methylene blue. Finally, the residual lesion was successfully removed, and the postoperative pathology confirmed that the resected lesion was a residual NET measuring 1.5 × .5 mm.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.